ADA Scientific Sessions Recap—Day #3: Dan Finan, Ph.D.
There was some really amazing results out here in San Francisco! Here is Dan Finan, Ph.D., head of the Breakthrough…
First Human Study to Significantly Delay—by Two Years!—Type 1 Diabetes Onset
This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immune…
Sanjoy Dutta, Ph.D.: The Beginning of the ADA Scientific Sessions
The ADA’s Scientific Sessions has begun! Here, in the first recap, is Sanjoy Dutta, Ph.D., who highlights beta cell replacement…
Breakthrough T1D Heads to ADA’s 79th Scientific Sessions
The American Diabetes Association’s (ADA) 79th Scientific Sessions is almost here! From June 7-11, in San Francisco, CA, scientists and…
Breakthrough T1D Beta Cell Replacement Consortium: Sharing data and resources, saving time and money
The Breakthrough T1D Spring Beta Cell Replacement Consortium meeting, held recently in NYC, allowed 55 researchers from a diversity of…
Proof-of-Concept for Hypoglycemia Prevention
Hypoglycemia, or low blood sugar, can have serious effects, and it is, for most people with type 1 diabetes (T1D),…
Breakthrough T1D Research Strategy: Cures and Improving Lives
They shared new developments and applauded the speed of scientific advancements. At this year’s Strategic Research Session, the tone was…
Your Cancer is Gone; Type 1 Diabetes is Here
Immune therapy has transformed cancer care. In some cases, cancer is effectively cured in people with stage 4 disease. But…
Advancing the Cure with Type 1 Diabetes Clinical Trials
Breakthrough T1D funds type 1 diabetes (T1D) clinical trials that are critical to bringing new devices and treatments to people…
Closer to Cure: Renewed Funding for Type 1 Diabetes UK Immunotherapy Consortium (T1D UK)
More than 400,000 people in the United Kingdom and 1.25 million Americans have type 1 diabetes (T1D), a disease for…
